DBPR108 tablets
Sponsors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions
Healthy SubjectsHepatic ImpairmentRenal ImpairmentType 2 Diabetes Mellitus
Phase 1
A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Hepatic Impairment
CompletedNCT04859426
Start: 2021-06-09End: 2022-05-17Updated: 2023-04-12
A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects
CompletedNCT04859452
Start: 2021-05-26End: 2021-07-09Updated: 2021-07-20
A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Renal Impairment
CompletedNCT04859439
Start: 2021-06-15End: 2021-12-31Updated: 2022-05-10
A Study to Evaluate the Drug-drug Interactions (DDIs) of DBPR108 With Warfarin Sodium, Digoxin, Probenecid in Healthy Subjects
CompletedNCT05045313
Start: 2021-10-20End: 2021-12-01Updated: 2022-03-10
A Single-dose and Multiple-dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of DBPR108 Tablets in Type 2 Diabetes Mellitus Patients
CompletedNCT05146869
Start: 2021-12-30End: 2022-03-28Updated: 2022-04-05
A Study to Evaluate the Effect of Different Meal Types on the Pharmacokinetics of DBPR108 in Healthy Subjects
CompletedNCT05150626
Start: 2022-05-29End: 2022-07-14Updated: 2023-04-12